Furthermore, pharmacological activation of S1pr1 significantly ameliorated pressure overload‐induced cardiac hypertrophy and fibrosis, and therefore improved cardiac function in vivo, suggesting that EC‐S1pr1 signals as a potential target to therapy heart failure. The gene discussed is S1PR1; the disease is heart failure.